Malaysian Genomics Resource Centre Bhd (XKLS:0155) Moat Score: 0/10 (As of Jul. 25, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XKLS:0155 Malaysian Genomics Resource Centre Bhd XKLS:0155
44 GF Score
Price RM0.30
GF Value RM0.31
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Malaysian Genomics Resource Centre Bhd Moat Score?

Malaysian Genomics Resource Centre Bhd has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Malaysian Genomics Resource Centre Bhd has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Malaysian Genomics Resource Centre Bhd might have No Moat - No discernible moat.

Malaysian Genomics Resource Centre Bhd  (XKLS:0155) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Malaysian Genomics Resource Centre Bhd Moat Score Related Terms

XKLS:0155
44GF Score
Malaysian Genomics Resource Centre Bhd XKLS:0155
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Malaysian Genomics Resource Centre Bhd (XKLS:0155) Overvalued in 2026?

Based on GuruFocus' analysis, Malaysian Genomics Resource Centre Bhd stock appears to be undervalued. The current stock price of RM0.30 is trading 4.8% below its estimated GF Value™ of RM0.31. GuruFocus considers Malaysian Genomics Resource Centre Bhd to be Fairly Valued.

Key valuation signals for XKLS:0155:

  • Moat Score: 0
  • GF Value™: RM0.31 vs. price of RM0.30 (4.8% below fair value)
  • GF Score™: 44/100 with 3 warning signs

No single metric tells the full story. See the XKLS:0155 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Malaysian Genomics Resource Centre Bhd Business Description

Address Jalan Teknologi 3/6, 8F, Taman Sains Selangor 1, Kota Damansara (PJU5), Petaling Jaya, SGR, MYS, 47810
Malaysian Genomics Resource Centre Bhd is a Malaysia-based company. The company's principal activities include enabling personalized and precision medicine through genetics, genomics, immunotherapy, and biopharmaceutical services, as well as investment holding. It offers genome sequencing and analysis (GSA) services and genetic screening services (GSS). The group offerings include precision genetic screening, project-based analysis, and high-quality cell therapy and cosmeceutical products. The reportable segments of the Group derive their revenue from the provision of personalised and precision medicine through genetics, genomics, immunotherapy, and biopharmaceutical services within the healthcare segment.
44GF Score

Get the complete analysis for XKLS:0155

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

RM0.30
Price
RM0.31
GF Value